School of Medicine
Showing 1-9 of 9 Results
Anne Lynn S. Chang, MD
Professor of Dermatology
Current Research and Scholarly InterestsI have two main research interests:
1) to better understand and treat patients with aggressive basal and squamous cell carcinomas
2) to better understand the genetic and epigenetic mechanisms of healthy human skin aging and to translate these insights into better care of skin diseases enriched in older patients particularly skin cancer and rosacea
Howard Y. Chang, MD, PhD
Virginia and D. K. Ludwig Professor of Cancer Research and Professor of Genetics
Current Research and Scholarly InterestsOur research is focused on how the activities of hundreds or even thousands of genes (gene parties) are coordinated to achieve biological meaning. We have pioneered methods to predict, dissect, and control large-scale gene regulatory programs; these methods have provided insights into human development, cancer, and aging.
Jennifer Chen, MD
Clinical Professor, Dermatology
BioJennifer K. Chen, M.D., is a Clinical Associate Professor of Dermatology. She co-directs the medical student sub-internship program. She completed medical school at Johns Hopkins University, residency at Johns Hopkins and University of California, Irvine, and completed a Howard Hughes Fellowship at Stanford University. Her clinical interests include contact dermatitis, atopic dermatitis, complex medical dermatology, skin cancer, and inpatient dermatology. She has served on the Board of Directors for the American Contact Dermatitis Society and as an invited member of the Contact Dermatitis Committee for the World Allergy Organization.
Richard Owguan Chen, MD
Clinical Assistant Professor, Dermatology
BioRichard Chen, M.D. M.S., is Clinical Assistant Professor of Dermatology at Stanford and Chief Scientific Officer at Personalis, Inc. He attended medical school and completed residency at Stanford University, serving as Chief Resident in his final year. His interests include general dermatology, cancer genomics, precision medicine, genetics, bioinformatics and technology innovation for improved health care delivery and therapy.
Albert Sean Chiou, MD, MBA
Clinical Associate Professor, Dermatology
Current Research and Scholarly InterestsI am a clinical researcher interested in evaluating promising new diagnostic paradigms and treatments for serious or poorly treated, chronic skin conditions. My research currently includes:
- Treatments for itch from epidermolysis bullosa
- Treatments for chronic wounds for patients with recessive dystrophic epidermolysis bullosa (In collaboration with Dr. Jean Tang and Dr. Peter Marinkovich)
- Treatments for atopic dermatitis, psoriasis, and other inflammatory skin conditions
- Artificial intelligence approaches for melanoma and skin cancer early detection
- Imaging mass spectrometry for skin cancer margin analysis and diagnosis
I collaborate with other faculty within the Stanford Skin Innovation and Interventional Research Group (SIIRG) to conduct investigator initiated and sponsored clinical trials seeking to improve care for important dermatologic diseases
Please learn more about our work at: https://siirg.stanford.edu/
Derek Chu, MD
Clinical Associate Professor, Dermatology
BioDerek Chu, M.D., is Clinical Associate Professor of Dermatology and Pediatrics at Lucile Packard Children's Hospital. He completed his medical school and residency training at the University of Pennsylvania, followed by a pediatric dermatology fellowship at UCSF. Dr. Chu's clinical interests encompass a wide array of topics within pediatric dermatology, including vascular tumors and malformations, inflammatory skin diseases, dermato-oncology, neonatal dermatology, and procedural dermatology.
Professor of Medicine (Immunology and Rheumatology) and, by courtesy, of Dermatology
Current Research and Scholarly InterestsMy research interests focus on all aspects of systemic sclerosis. I am currently involved in clinical, translational, and epidemiologic research in these areas, and dedicate a substantial portion of my research time to investigator-initiated and multi-center clinical trials of novel therapeutics for the treatment of systemic sclerosis.